BidaskClub lowered shares of Stemline Therapeutics (NASDAQ:STML) from a buy rating to a hold rating in a report released on Wednesday.
STML has been the subject of several other reports. Zacks Investment Research raised Stemline Therapeutics from a sell rating to a hold rating in a research report on Friday, January 5th. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a buy rating in a research report on Monday. Finally, ValuEngine cut Stemline Therapeutics from a hold rating to a sell rating in a research report on Tuesday, March 13th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $31.33.
STML stock opened at $13.85 on Wednesday. The company has a market capitalization of $415.39, a price-to-earnings ratio of -4.71 and a beta of -0.07. Stemline Therapeutics has a 12-month low of $7.30 and a 12-month high of $18.75.
Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.26). Stemline Therapeutics had a negative return on equity of 94.70% and a negative net margin of 4,689.63%. equities analysts predict that Stemline Therapeutics will post -1.68 EPS for the current fiscal year.
In other Stemline Therapeutics news, COO Kenneth Hoberman sold 14,040 shares of Stemline Therapeutics stock in a transaction on Monday, January 8th. The stock was sold at an average price of $13.93, for a total transaction of $195,577.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ivan Bergstein sold 3,820 shares of Stemline Therapeutics stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $15.80, for a total value of $60,356.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 156,418 shares of company stock valued at $2,628,131. Company insiders own 15.70% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Consonance Capital Management LP lifted its holdings in shares of Stemline Therapeutics by 2,216.9% during the fourth quarter. Consonance Capital Management LP now owns 2,349,792 shares of the biopharmaceutical company’s stock valued at $36,657,000 after acquiring an additional 2,248,372 shares during the period. BlackRock Inc. lifted its holdings in shares of Stemline Therapeutics by 6.3% during the fourth quarter. BlackRock Inc. now owns 1,406,181 shares of the biopharmaceutical company’s stock valued at $21,936,000 after acquiring an additional 83,044 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Stemline Therapeutics by 4.7% during the second quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock valued at $7,946,000 after acquiring an additional 38,615 shares during the period. Lyon Street Capital LLC lifted its holdings in shares of Stemline Therapeutics by 53.1% during the fourth quarter. Lyon Street Capital LLC now owns 829,090 shares of the biopharmaceutical company’s stock valued at $12,934,000 after acquiring an additional 287,628 shares during the period. Finally, State Street Corp lifted its holdings in shares of Stemline Therapeutics by 11.3% during the second quarter. State Street Corp now owns 345,363 shares of the biopharmaceutical company’s stock valued at $3,179,000 after acquiring an additional 35,116 shares during the period. 52.00% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://ledgergazette.com/2018/03/22/stemline-therapeutics-stml-downgraded-to-hold-at-bidaskclub.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.